Related Experiment Video
Updated: Jul 14, 2026

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
Published on: October 28, 2019
Antisense RNA directed to the human papillomavirus type 16 E7 mRNA from herpes simplex virus type 1 derived vectors
Ilkka Kari1, Stina Syrjänen, Bo Johansson
1Department of Virology, Institute of Dentistry, University of Turku, Turku, Finland. ilanka@utu.fi
Background:
Human papillomavirus (HPV) infection is known to be the most important etiologic factor of cervical cancer. There is no HPV specific therapy available for treatment of invasive squamous cell carcinoma of the cervix and its precursor lesions. The present study elucidates the potential to use herpes simplex virus (HSV) derived vectors for expression of antisense RNA to HPV -16 E7 oncogene.
Results:
We have constructed replication competent, nonneuroinvasive HSV-1 vectors, deleted of the gamma134.5 gene. The vectors express RNA antisense to the first 100 nucleotides of the HPV-16 E7 gene. We assayed the ability of the antisense E7 vectors R5225 (tk-) and R5226 (tk+), to produce antisense RNA, as well as the consequent effects on E7 mRNA and protein levels in HPV-16 positive CaSki cells. Anti-E7 RNA was expressed by both constructs in a dose-dependent manner. Expression of HPV-16 E7 mRNA was downregulated effectively in CaSki cells infected with the tk- recombinant R5225 or with R5226. The tk+ recombinant R5226 was effective in downregulating E7 protein expression.
Conclusion:
We have shown that anti-E7 RNA expressed from an HSV vector could efficiently downregulate HPV-16 E7 mRNA and E7 protein expression in CaSki cells. We conclude that HSV vectors may become a useful tool for gene therapy of HPV infections.
Insights
Herpes simplex virus (HSV) vectors expressing antisense RNA effectively reduced human papillomavirus (HPV) oncogene E7 mRNA and protein in cervical cancer cells. This suggests HSV vectors show promise for HPV gene therapy.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Human papillomavirus (HPV) is a primary cause of cervical cancer.
- Current treatments lack HPV-specific therapies for invasive cervical cancer and precursor lesions.
Purpose of the Study:
- To investigate the potential of herpes simplex virus (HSV) vectors for expressing antisense RNA targeting the HPV-16 E7 oncogene.
Main Methods:
- Constructed replication-competent, nonneuroinvasive HSV-1 vectors lacking the gamma134.5 gene.
- Vectors expressed RNA antisense to the HPV-16 E7 gene's initial 100 nucleotides.
- Assayed E7 mRNA and protein downregulation in HPV-16 positive CaSki cells using R5225 (tk-) and R5226 (tk+) vectors.
Main Results:
- Both HSV vectors successfully produced antisense E7 RNA in a dose-dependent manner.
- Expression of HPV-16 E7 mRNA was significantly downregulated in CaSki cells infected with R5225 or R5226.
- The tk+ recombinant vector (R5226) effectively downregulated E7 protein expression.
Conclusions:
- Antisense RNA delivered via HSV vectors efficiently reduced HPV-16 E7 mRNA and protein levels in CaSki cells.
- HSV vectors represent a potential therapeutic tool for gene therapy targeting HPV infections.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Herpes
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Viruses with RNA Genomes

